MetaVia (MTVA)
NASDAQ:MTVA
Top Page
MetaVia
(NASDAQ:MTVA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(22.95% Upside)
Action:ReiteratedDate:03/27/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses and cash burn, and equity erosion) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates around DA-1726 and obesity/MASH positioning provide some support, but valuation remains constrained by ongoing unprofitability.
Positive Factors
Strong patent estate for DA-1726
A broad patent estate covering DA-1726 through 2041 provides multi-year exclusivity potential, strengthening commercialization leverage and licensing appeal. Patents reduce competitive erosion risk, support partner negotiations, and protect long-term value if clinical development succeeds.
Negative Factors
No revenue; ongoing losses
Absence of product revenue means the business depends entirely on capital markets and milestone funding; recurring operating losses limit internal reinvestment and extend time to self-sufficiency. Long-term viability hinges on successful clinical outcomes and commercialization execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong patent estate for DA-1726
A broad patent estate covering DA-1726 through 2041 provides multi-year exclusivity potential, strengthening commercialization leverage and licensing appeal. Patents reduce competitive erosion risk, support partner negotiations, and protect long-term value if clinical development succeeds.
Read all positive factors
MetaVia (MTVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.21M
Dividend YieldN/A
Average Volume (3M)3.42M
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue GrowthN/A
EPS Growth71.57%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.01
Shares Outstanding5,090,936
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit527.30
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$14.00Price Target Upside1047.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.97
Revenue Forecast (FY)N/A
MetaVia Business Overview & Revenue Model
Company Description
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionalit...
MetaVia Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -19.00K | -24.00K | -7.00K | -28.00K | -72.00K |
| EBITDA | -13.69M | -28.79M | -15.88M | -11.76M | -15.24M |
| Net Income | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M |
Balance Sheet | |||||
| Total Assets | 69.12M | 16.26M | 22.78M | 33.53M | 16.80M |
| Cash, Cash Equivalents and Short-Term Investments | 10.28M | 16.02M | 22.43M | 33.36M | 16.39M |
| Total Debt | 210.00K | 136.00K | 203.00K | 0.00 | 71.00K |
| Total Liabilities | 63.79M | 8.33M | 6.10M | 11.78M | 2.20M |
| Stockholders Equity | 5.33M | 7.93M | 16.68M | 21.75M | 14.60M |
Cash Flow | |||||
| Free Cash Flow | -15.70M | -24.72M | -10.85M | -11.71M | -15.14M |
| Operating Cash Flow | -15.70M | -24.71M | -10.80M | -11.71M | -15.13M |
| Investing Cash Flow | -2.00K | -8.00K | -50.00K | 8.00K | -586.00K |
| Financing Cash Flow | 9.96M | 18.30M | -80.00K | 28.68M | 22.03M |
MetaVia Technical Analysis
Negative
1.22
Price Trends
1.67
Negative
4.75
Negative
6.80
Negative
Market Momentum
-0.22
Negative
30.01
Neutral
20.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTVA, the sentiment is Negative. The current price of 1.22 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.67, and below the 200-day MA of 6.80, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 30.01 is Neutral, neither overbought nor oversold. The STOCH value of 20.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTVA.
MetaVia Risk Analysis
MetaVia disclosed 67 risk factors in its most recent earnings report. MetaVia reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MetaVia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $42.95M | -3.44 | -16.25% | ― | 12.71% | 79.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $23.59M | -0.30 | 9999.00% | ― | ― | -273.84% | |
48 Neutral | $19.24M | -0.51 | -54.40% | ― | ― | 18.73% | |
46 Neutral | $6.21M | -2.52 | -229.48% | ― | ― | 71.57% |
* Healthcare Sector Average
MTVA
MetaVia
1.22
-14.19
-92.08%
PMN
ProMIS Neurosciences
10.96
-3.61
-24.76%
CTXR
Citius Pharmaceuticals
0.86
-0.19
-18.19%
RLYB
Rallybio
8.12
4.72
138.89%
KAPA
Kairos Pharma, Ltd.
0.62
-0.52
-45.61%
MetaVia Corporate Events
Business Operations and Strategy
MetaVia Updates Investor Strategy for Obesity and MASH
Positive
Mar 26, 2026
On March 26, 2026, MetaVia Inc. reported that it had posted an updated investor presentation outlining its strategy to address obesity and MASH, two large and rapidly expanding therapeutic markets with projected annual sales in the tens of billion...
Business Operations and StrategyProduct-Related Announcements
MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3
Positive
Mar 18, 2026
On March 18, 2026, MetaVia Inc. announced that an Institutional Review Board at Clinical Pharmacology of Miami approved Part 3 of its Phase 1 clinical trial for DA-1726, its lead GLP-1 and glucagon dual agonist for obesity. The new 16-week study w...
Executive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
MetaVia Updates 2025 Executive Discretionary Bonus Disclosure
Neutral
Jan 27, 2026
On January 5, 2026, MetaVia Inc. filed a registration statement that referenced yet-to-be-determined discretionary cash bonuses for its principal executive officer and up to two other highly compensated executives for the fiscal year ended Decembe...
Business Operations and StrategyPrivate Placements and Financing
MetaVia Completes Public Offering to Advance Obesity Drug
Positive
Jan 16, 2026
On January 15–16, 2026, MetaVia Inc. completed an underwritten public offering of Class A and Class B units, consisting of common stock, pre-funded warrants and Series C and Series D common warrants, raising approximately $7.7 million in net...
Business Operations and StrategyProduct-Related Announcements
MetaVia Reports Encouraging Phase 1 DA-1726 Obesity Data
Positive
Jan 5, 2026
On January 5, 2026, MetaVia reported positive, statistically significant data from the extended eight-week, non-titrated 48 mg multiple ascending dose cohort of its Phase 1 clinical trial of DA-1726 in obese but otherwise healthy adults, highlight...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.